Early accelerated approval for highly targeted cancer drugs

New England Journal of Medicine

Volumn 364, Issue 12, 2011, Pages 1087-1089

  Chabner, Bruce A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANTINEOPLASTIC AGENT; B RAF KINASE; BCR ABL PROTEIN; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GEMTUZUMAB; PLX 4032;

CANCER GROWTH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG APPROVAL; DRUG TARGETING; DRUG TREATMENT FAILURE; HEALTH CARE ACCESS; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; MUTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; STANDARD; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 79953193825     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1100548     Document Type: Short Survey

References (5)

1. Miller FG, Joffe S. Equipose and the dilemma of randomized clinical trials. N Engl J Med 2011;364:476-80.
2. McClellan M, Benner J, Schilsky R, et al. An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov 2011;10:79-80.
3. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26: 2442-9. [Erratum, J Clin Oncol 2008;26:3472.]
4. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
5. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703. [Erratum, N Engl J Med 2011;364:588.]